< How many Texans have been on the Supreme Court? | Main | WSJ profiles David Adickes >
January 17, 2006
Boston Scientific won't take no for an answer
Gosh, just a little over two months ago, Johnson & Johnson was threatening to walk on its proposed $25.4 billion ($76 per share) merger with Guidant. J&J eventually agreed to stay in the deal after Guidant agreed that J&J could knock $4 billion off the purchase price.
But then, Boston Scientific got in the game for Guidant. Before you know it, J&J was making nice with Guidant and had increased its bid for Guidant back up to $24.2 billion ( $40.52 in cash and .493 shares of J&J stock for each Guidant share) with a quick closing date. Guidant's board accepted that revised offer and J&J heaved a sigh of relief until . . .
Boston Scientific announced this morning that it had increased its bid for Guidant to an eye-popping $80 a share or more than $27 billion. With that offer, it now appears that J&J may have to raise its offer to above the $25.4 billion, $76 per share offer that J&J originally agreed to pay for Guidant.
Does anyone else get the sense that J&J wished it had never heard of such things as "material adverse effects" and Eliot Spitzer?
Update: And Guidant has switched allegiances and now supports Boston Scientific's new bid.
Posted by Tom at January 17, 2006 08:08 AM
Trackback Pings
TrackBack URL for this entry:
http://mtcgi.kir.com/mt-trackbk.cgi/2793
Comments
Post a comment
Thanks for signing in, . Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)